Sanofi has selected Paul Hudson, Novartis' pharma chief, to serve as its new CEO, according to Bloomberg.
Mr. Hudson will replace Oliver Brandicourt, who will retire in September at the age of 63. Mr. Brandicourt has served as CEO of the drugmaker since 2015.
Mr. Hudson has led Novartis' pharma unit since 2016 and is credited with launching key medicines for the drugmaker. Before coming to Novartis, Mr. Hudson served as the U.S. pharma chief for AstraZeneca.
Marie-France Tschudin will become the new leader of the Novartis pharmaceuticals business unit.